The antimutagenic and cytoprotective effects of amifostine: The role of p53

Journal of Applied Biomedicine

Volumn 5, Issue 4, 2007, Pages 171-178

  Grochová, Diana ^a,b   Šmardová, Jana ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Amifostine; Cytoprotective and antimutagenic compounds; Tumour suppressor p53; WR 1065; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACETYLCYSTEINE; AMIFOSTINE; ANTINEOPLASTIC AGENT; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; GLUTATHIONE; MESNA; PROTEIN P53; RAZOXANE; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROTECTION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SELECTIVITY; HUMAN; HYPOCALCEMIA; HYPOTENSION; INHIBITION KINETICS; MEDICAL RESEARCH; METASTASIS INHIBITION; NAUSEA; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITY OF LIFE; RADIATION INJURY; REVIEW; SIDE EFFECT; SNEEZING; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 37549052483     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.32725/jab.2007.023     Document Type: Review

References (53)

1. Acosta JC, Richard C, Delgado MD, Horita M, Rizzo MG, Fernandez-Luna JL, Leon J: Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol. Cancer. Ther. 2:893-900, 2003.
2. Andreassen CN, Grau C, Lindegaard J C: Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin. Radiat. Oncol. 13:62-72, 2003.
3. Appella E, Anderson CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772, 2001.
4. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC: Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 48:3634-3640, 1988.
5. Camhi SL, Lee P, Choi AM: The oxidative stress response. New Horiz. 3:170-182, 1995.
6. Capizzi RL: The preclinical basis for broad-spectrum selective, cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol. 26:3-21, 1999.
7. Culy CR, Spencer CM: Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684, 2001.
8. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA: Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res. 48:6002-6005, 1988.
9. Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T: Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 16:1369-1372, 1998.
10. Grdina DJ, Murley JS, Kataoka Y, Epperly W: Relationships between cytoprotection and mutation prevention by WR-1065. Mil. Med. 167:51-53, 2002a.
11. Grdina DJ, Murley JS, Kataoka Y: Radioprotectants: current status and new directions. Oncology 63:2-10, 2002b.
12. Hainaut P, Milner J: Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53:4469-4473, 1993.
13. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr., Mitchell RB, Negrin R, Szatrowski TP, et al.: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17:3333-3355, 1999.
14. http://www.drugs.com, downloaded 28th February 2007.
15. Kataoka Y, Murley JS, Patel R, Grdina DJ: Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. Int. J. Radiat. Biol. 76:633-639, 2000.
16. Koukourakis MI: Amifostine: is there evidence of tumour protection? Semin. Oncol. 30:18-30, 2003.
17. Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW: Polyamine analogue induction of the p53-p21 WAF1/ CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59:1278-1286, 1999.
18. Lee E, Gerhold M, Palmer MW, Christen RD: p53 protein regulates the effects of amifostine on apoptosis, cell cycle progression, and cytoprotection. Br. J. Cancer. 88:754-759, 2003.
19. Liu SC, Murley JS, Woloschak, Grdina DJ: Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18:2457-2459, 1997.
20. Mann K, Hainaut P: Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53. Oncogene 24:3964-3975, 2005.
21. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P: Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 20:3533-3540, 2001.
22. MedImmune Oncology, Inc.: Ethyol Monograph. Package Insert, Gaithersburg, MD 2005.
23. Meier T, Issels RD: Degradation of 2-(3- aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem. Pharmacol. 50:489-496, 1995.
24. Milner J: Flexibility: The key to p53 function? Trends Biochem. Sci. 20:49-51, 1995.
25. Minet E, Michel G, Mottet D, Piret JP, Barbieux A, Raes M, Michiels C: c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp. Cell. Res. 265:114-124, 2001.
26. Mitchell JL, Rupert J, Leyser A, Judd GG: Mammalian cell polyamine homeostasis is altered by the radioprotector WR1065. Biochem. J. 335:329-334, 1998.
27. Murley JS, Constantinou A, Kamath NS, Grdina DJ: WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to ebanges in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 30:283-294, 1997.
28. Murley JS, Grdina DJ: The effects of cycloheximide and WR-1065 on radiation-induced repair processes: A mechanism for chemoprevention. Carcinogenesis 16:2699-2705, 1995.
29. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ: Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic. Biol. Med. 30:1426-1439, 2001.
30. North S, El-Ghissassi F, Pluquet O, Verhaegh G, Hainaut P: The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through, a p53-dependent pathway. Oncogene, 19:1206-1214, 2000.
31. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P: Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinog. 33:181-188, 2002.
32. Paasinen-Sohns A, Kielosto M, Kaariainen E, Eloranta T, Laine A, Janne OA, Birrer MJ, Holtta E: c-Jun activation-dependent tumourigenic transformation induced paradoxically by overexpression or block of S- adenosylmethionine decarboxylase. J. Cell. Biol. 151:801-810, 2000.
33. Pataer A, Fanale MA, Roth JA, Swisher SG, Hunt KK: Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther. 13:806-814, 2006.
34. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P: The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J. Biol. Chem. 278:11879-11887, 2003a.
35. Pluquet O, North S, Richard MJ, Hainaut P: Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem. Pharmacol. 65:1129-1137, 2003b.
36. Pollard KJ, Samuels ML, Crowley KA, Hansen JC, Peterson CL: Functional interaction between GCN5 and polyamines: A new role for core histone acetylation. EMBO J. 18: 5622-5633, 1999.
37. Prives C, Hall PA: The p53 pathway. J. Pathol. 187:112-126, 1999.
38. Provinciali M, Ciavattini A, Di Stefano G, Argentati K, Garzetti GG: In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci. 64:1525-1532, 1999.
39. Ramakrishnan N, Catravas GN: N-(2-mercaptoethyl)-1,3-propanediamine (WR-1065) protects thymocytes from programmed cell death. J. Immunol. 148:1817-1821, 1992.
40. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, Tassone P, Turco MC, Venuta S: Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors. Blood 94:4060-4066, 1999.
41. Santini V, Giles FJ: The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 84:1035-1042, 1999.
42. Savoye C, Swenberg C, Hugot S, Sy D, Sabattier R, Charlier M, Spotheim-Maurizot M: Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int. J. Radiat. Biol. 71:193-202, 1997.
43. Shaw L M, Bonner HS, Schuchter L, Schiller J, Lieberman R: Pharmacokinetics of amifostine: effects of dose and method of administration. Semin. Oncol. 26:34-36, 1999.
44. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD: Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297:1067-1073, 2001.
45. Sherr CJ, Weber JD: The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10:94-99, 2000.
46. Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6:909-923, 2006.
47. van der Vijgh WJ, Korst AE: Amifostine (Ethyol): Pharmacokinetic and pharmacodynamic effects in vivo. Eur. J. Cancer 32:S26-S30, 1996.
48. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604, 2002.
49. Vousden KH: Activation of the p53 tumour suppressor protein. Biochim. Biophys. Acta 1602:47-59, 2002.
50. Wadler S, Haynes H, Beitler JJ, Goldberg G, Holland JF, Hochster H, Bruckner H, Mandeli J, Smith H, Runowicz C: Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. J. Clin. Oncol. 11: 1517-1522, 1993.
51. Woloschak G E, Paunesku T, Chang-Liu CM, Grdina DJ: Expression of thymidine kinase messenger RNA and a related transcript is modulated by radioprotector WR1065. Cancer Res. 55:4788-4792, 1995.
52. Yuhas JM, Storer JB: Differential chemoprotection of normal and malignant tissues. J. Natl. Cancer Inst. 42:331-335, 1969.
53. Zhang X, Lai PP, Taylor YC: Differential radioprotection of cultured human diploid fibroblasts and fibrosarcoma cells by WR1065. Int. J. Radiat. Oncol. Biol. Phys. 24:713-719, 1992.